

ERBB2 Antibody (C-term Y1112/S1113) Blocking Peptide
Synthetic peptide
Catalog # BP18892b**Specification****ERBB2 Antibody (C-term Y1112/S1113) Blocking Peptide - Product Information**Primary Accession [P04626](#)**ERBB2 Antibody (C-term Y1112/S1113) Blocking Peptide - Additional Information****Gene ID** 2064**Other Names**

Receptor tyrosine-protein kinase erbB-2,
Metastatic lymph node gene 19 protein,
MLN 19, Proto-oncogene Neu,
Proto-oncogene c-ErbB-2, Tyrosine
kinase-type cell surface receptor HER2,
p185erbB2, CD340, ERBB2, HER2, MLN19,
NEU, NGL

Format

Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.

Storage

Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.

Precautions

This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.

ERBB2 Antibody (C-term Y1112/S1113) Blocking Peptide - Protein Information**Name** ERBB2**Synonyms** HER2, MLN19, NEU, NGL**Function**

Protein tyrosine kinase that is part of
several cell surface receptor complexes, but
that apparently needs a coreceptor for

**ERBB2 Antibody (C-term Y1112/S1113)
Blocking Peptide - Background**

This gene encodes a member of the epidermal
growth factor(EGF) receptor family of receptor
tyrosine kinases. This protein has no ligand
binding domain of its own and therefore cannot
bind growth factors. However, it does bind
tightly to other ligand-bound EGF receptor
family members to form a heterodimer,
stabilizing ligand binding and enhancing
kinase-mediated activation of downstream
signalling pathways, such as those
involving mitogen-activated protein kinase and
phosphatidylinositol-3 kinase. Allelic variations
at amino acid positions 654 and 655 of isoform
a (positions 624 and 625 of isoform b) have
been reported, with the most common allele,
Ile654/Ile655, shown here. Amplification
and/or overexpression of this gene has been
reported in numerous cancers, including breast
and ovarian tumors. Alternative splicing
results in several additional transcript variants,
some encoding different isoforms and others
that have not been fully characterized.

**ERBB2 Antibody (C-term Y1112/S1113)
Blocking Peptide - References**

Geradts, J., et al. Cancer Invest.
28(9):969-977(2010) Zaoui, K., et al. Proc. Natl.
Acad. Sci. U.S.A.
107(43):18517-18522(2010) Oliveras, G., et al.
Ann. N. Y. Acad. Sci. 1210, 86-92 (2010) :Han,
J.S., et al. Anticancer Res.
30(9):3407-3412(2010) Stackiewicz, R., et al.
Isr. Med. Assoc. J. 12(5):290-295(2010)

ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein Early endosome. Cytoplasm, perinuclear region. Nucleus. Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1. Also detected in VPS35-positive endosome-to-TGN retrograde vesicles (PubMed:31138794). [Isoform 3]: Cytoplasm. Nucleus.

Tissue Location

Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.

**ERBB2 Antibody (C-term Y1112/S1113)
Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)